CoChat
Sign Up
Cited by 106Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsEndometriosis Research and Treatment

Longterm management of Polycystic Ovarian Syndrome (PCOS)

Open access
Bates, Gordon W., Legro, Richard S.·2013·Molecular and Cellular Endocrinology
DOI 10.1016/j.mce.2012.10.029PMC PMC4367484
Open this paper in CoChat — free account

Abstract

Polycystic Ovarian Syndrome (PCOS) has been associated with numerous reproductive and metabolic abnormalities. Despite tremendous advances in the management of reproductive dysfunction, insight into the metabolic implications of PCOS is limited by the lack of uniform diagnostic criteria, the heterogeneity of the condition and the presence of confounders including obesity. Obesity clearly has a role in long term health and may best predict both reproductive and metabolic dysfunction as well as negatively affect the response to treatment in women with PCOS. Diabetes, cardiovascular disease and cancer are also at the forefront of any risk assessment or comprehensive treatment strategy for these women. Lifestyle modifications including dietary changes, increased exercise and weight loss are appropriate first line interventions for many women with PCOS. Pharmaceuticals including metformin, lipid lowering agents and oral contraceptives should be tailored to the individual's risk profile and treatment goals.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mce.2012.10.029

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 79 · Cited by 106

Research works printed but not linked: 57

  1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 9131 854 65 9742977
  2. Adami HO Hunter D Trichopoulos D 2009 PtOSOS Textbook of Cancer Epidemiology 2008 Oxford University Press
  3. Agarwal N Rice SP Bolusani H Luzio SD Dunseath G Ludgate M Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial J Clin Endocrinol Metab 2010 95 2 722 30 19996308
  4. Andersen P Seljeflot I Abdelnoor M Arnesen H Dale PO Lovik A Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome Metabolism 1995 44 5 611 6 7752909
  5. Benson S Arck PC Tan S Hahn S Mann K Rifaie N Disturbed stress responses in women with polycystic ovary syndrome Psychoneuroendocrinology 2009 34 5 727 35 19150179
  6. Boggs DA Rosenberg L Cozier YC Wise LA Coogan PF Ruiz-Narvaez EA General and abdominal obesity and risk of death among black women N Engl J Med 2011 365 10 901 8 21899451 PMC3206314
  7. Brown ZA Louwers YV Fong SL Valkenburg O Birnie E de Jong FH The phenotype of polycystic ovary syndrome ameliorates with aging Fertil Steril 2011 96 5 1259 65 21963227
  8. Carmina E Campagna AM Lobo RA A 20-year follow-up of young women with polycystic ovary syndrome Obstet Gynecol 2012 119 2 Pt 1 263 9 22270277
  9. Chang CM Wang SS Dave BJ Jain S Vasef MA Weisenburger DD Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study Int J Cancer 2011 129 4 938 47 20949561 PMC3125462
  10. Chittenden BG Fullerton G Maheshwari A Bhattacharya S Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review Reprod Biomed Online 2009 19 3 398 405 19778486
  11. Clark AM Thornley B Tomlinson L Galletley C Norman RJ Weight loss in obese infertile women results in improvement in reproductive outcomes for all forms of fertility treatment Hum Reprod 1998 13 6 1502 5 9688382
  12. Costello MF Shrestha B Eden J Johnson NP Sjoblom P Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review Hum Reprod 2007 22 5 1200 9 17261574
  13. Coulam CB Annegers JF Kranz JS Chronic anovulation syndrome and associated neoplasia Obstet Gynecol 1983 61 4 403 7 6828267
  14. Cramer DW The epidemiology of endometrial and ovarian cancer Hematol Oncol Clin North Am 2012 26 1 1 12 22244658 PMC3259524
  15. Crosignani PG Colombo M Vegetti W Somigliana E Gessati A Ragni G Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet Hum Reprod 2003 18 9 1928 32 12923151
  16. Diamanti-Kandarakis E Alexandraki K Protogerou A Piperi C Papamichael C Aessopos A Metformin administration improves endothelial function in women with polycystic ovary syndrome Eur J Endocrinol 2005 152 5 749 56 15879361
  17. Derosa G Cicero AF D’Angelo A Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes J Clin Pharm Ther 2012 37 2 187 95 21812797
  18. Dokras A Clifton S Futterweit W Wild R Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis Obstet Gynecol 2011 117 1 145 52 21173657
  19. Ehrmann DA Liljenquist DR Kasza K Azziz R Legro RS Ghazzi MN Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome J Clin Endocrinol Metab 2006 91 1 48 53 16249284
  20. Escobar-Morreale HF Botella-Carretero JI Alvarez-Blasco F Sancho J San Millan JL The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery J Clin Endocrinol Metab 2005 90 12 6364 9 16189250
  21. Fauser BC Tarlatzis BC Rebar RW Legro RS Balen AH Lobo R Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group Fertil Steril 2012 97 1 28 38 e25 22153789
  22. Gallos ID Shehmar M Thangaratinam S Papapostolou TK Coomarasamy A Gupta JK Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis Am J Obstet Gynecol 2010 203 6 547 e1 10 20934679
  23. Garvey WT Ryan DH Look M Gadde KM Allison DB Peterson CA Two-year sustained weight loss an dmetabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study Am J Clin Nutr 2012 95 2 297 308 22158731 PMC3260065
  24. Glintborg D Mumm H Ravn P Andersen M Age Associated Differences in Prevalence of Individual Rotterdam Criteria and Metabolic Risk Factors during Reproductive Age in 446 Caucasian Women with Polycystic Ovary Syndrome Horm Metab Res 2012 22382934
  25. Glueck CJ Dharashivkar S Wang P Zhu B Gartside PS Tracy T Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy Eur J Obstet Gynecol Reprod Biol 2005 122 2 206 12 16219521
  26. Guzick DS Polycystic ovary syndrome Obstet Gynecol 2004 103 1 181 93 14704263
  27. Hall KD Sacks G Chandramohan D Chow CC Wang YC Gortmaker SL Quantification of the effect of energy imbalance on bodyweight Lancet 2011 378 9793 826 37 21872751 PMC3880593
  28. Hemminki K Li X Sundquist J Sundquist K Risk of cancer following hospitalization for type 2 diabetes Oncologist 2010 15 6 548 55 20479278 PMC3227990
  29. Hollmann M Runnebaum B Gerhard I Effects of weight loss on the hormonal profile in obese, infertile women Hum Reprod 1996 11 9 1884 91 8921059
  30. Kiddy DS Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome Clin Endocrinol (Oxf) 1992 36 1 7 1559293
  31. Knochenhauer ES Key TJ Kahsar-Miller M Waggoner W Boots LR Azziz R Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study J Clin Endocrinol Metab 1998 83 9 3078 82 9745406
  32. Knowler WC Hamman RF Edelstein SL Barrett-Connor E Ehrmann DA Walker EA Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program Diabetes 2005 54 4 1150 6 15793255 PMC1351025
  33. Korhonen S Hippelainen M Niskanen L Vanhala M Saarikoski S Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study Am J Obstet Gynecol 2001 184 3 289 96 11228476
  34. Legro RS Kunselman AR Dunaif A Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome Am J Med 2001 111 8 607 13 11755503
  35. Legro RS Gnatuk CL Kunselman AR Dunaif A Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study J Clin Endocrinol Metab 2005 90 6 3236 42 15797965
  36. Legro RS Barnhart HX Schlaff WD Carr BR Diamond MP Carson SA Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome N Engl J Med 2007 356 6 551 66 17287476
  37. Legro RS Zaino RJ Demers LM Kunselman AR Gnatuk CL Williams NI The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome Am J Obstet Gynecol 2007 196 4 402 e1 10 discussion e10-1. 17403436
  38. Linkov F Maxwell GL Felix AS Lin Y Lenzner D Bovbjerg DH Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: Implications for cancer risk reduction Gynecol Oncol 2011 PMC4387771 22198242
  39. Lord J Thomas R Fox B Acharya U Wilkin T The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome BJOG 2006 113 10 1203 9 16753044
  40. Luke B Brown MB Missmer SA Bukulmez O Leach R Stern JE The effect of increasing obesity on the response to and outcome of assisted reproductive technology: a national study Fertil Steril 2011 96 4 820 5 21821244
  41. Moran LJ Pasquali R Teede HJ Hoeger KM Norman RJ Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society Fertil Steril 2009 92 6 1966 82 19062007
  42. Moran LJ Hutchison SK Norman RJ Teede HJ Lifestyle changes in women with polycystic ovary syndrome Cochrane Database Syst Rev 2011 7 CD007506 21735412
  43. Morin-Papunen L Rautio K Ruokonen A Hedberg P Puukka M Tapanainen JS Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome J Clin Endocrinol Metab 2003 88 10 4649 54 14557435
  44. Nandalike K Agarwal C Strauss T Coupey SM Isasi CR Sin S Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome Sleep Med 22 8 2012 [Epub ahead of print] PMC3509263 22921588
  45. Norman RJ Masters L Milner CR Wang JX Davies MJ Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome Hum Reprod 2001 16 9 1995 8 11527911
  46. Orchard TJ Temprosa M Goldberg R Haffner S Ratner R Marcovina S The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial Ann Intern Med 2005 142 8 611 9 15838067 PMC2505046
  47. Palomba S Falbo A Giallauria F Russo T Rocca M Tolino A Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial Hum Reprod 2010 25 11 2783 91 20858697
  48. Park HS Lee K Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity Diabet Med 2005 22 3 266 72 15717873
  49. Pasquali R Stener-Victorin E Yildiz BO Duleba AJ Hoeger K Mason H PCOS Forum: research in polycystic ovary syndrome today and tomorrow Clin Endocrinol (Oxf) 2011 74 4 424 33 21158892 PMC3742326
  50. Poddar K Kolge S Bezman L Mullin GE Cheskin LJ Nutraceutical Supplements for Weight Loss A Systematic Review Nutr Clin Pract 10 2011 26 5 539 52 21947637
  51. Rosato V Zucchetto A Bosetti C Dal Maso L Montella M Pelucchi C Metabolic syndrome and endometrial cancer risk Ann Oncol 2011 22 4 884 9 20937645
  52. Rosenzweig JL Ferrannini E Grundy SM Haffner SM Heine RJ Horton ES Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline J Clin Endocrinol Metab 2008 93 10 3671 89 18664543
  53. Shufelt CL Johnson BD Berga SL Braunstein GD Reis SE Bittner V Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation Menopause 2011 18 9 943 50 21532511 PMC3747738
  54. Talbott EO Guzick DS Sutton-Tyrrell K McHugh-Pemu KP Zborowski JV Remsberg KE Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women Arterioscler Thromb Vasc Biol 2000 20 11 2414 21 11073846
  55. Tang T Glanville J Hayden CJ White D Barth JH Balen AH Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006 21 1 80 9 16199429
  56. Taylor MC Reema Kar A Kunselman AR Stetter CM Dunaif A Legro RS Evidence for increased cardiovascular events in the fathers but not mothers of women with polycystic ovary syndrome Hum Reprod 2011 26 8 2226 31 21505042 PMC3137384
  57. Wang ET Calderon-Margalit R Cedars MI Daviglus ML Merkin SS Schreiner PJ Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia Obstet Gynecol 2011 117 1 6 13 21173640 PMC3060760

Authors
Bates, G. W., & Legro, R. S.
Affiliations
University of Alabama at Birmingham (US)
Corresponding author
Bates, Gordon W.
ORCID
Venue
Molecular and Cellular Endocrinology
Publisher
Elsevier BV
Published
2013-07
Volume
373
Issue
1-2
Pages
91-97
ISSN
0303-7207 (ISSN-L)
DOI
10.1016/j.mce.2012.10.029
PMC
PMC4367484
OpenAlex
W1978371060
Cited by
106
References
79
Citations by year
2026: 6 · 2025: 8 · 2024: 4 · 2023: 9 · 2022: 13 · 2021: 5 · 2020: 7 · 2019: 11 · 2018: 14 · 2017: 5 · 2016: 5 · 2015: 7 · 2014: 10 · 2013: 2
FWCI
0.83
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Molecular and Cellular Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10HD038992)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
polycystic ovary syndrome, long-term management, obesity, metabolic dysfunction, reproductive disorders, diabetes risk, cardiovascular risk, cancer risk, lifestyle modification, weight loss, metformin, lipid-lowering drugs, oral contraceptives, diagnostic criteria
MeSH terms
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diet Therapy, Exercise Therapy, Female, Humans, Neoplasms, Obesity, Polycystic Ovary Syndrome, Risk Factors, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review